Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma

Renal cell carcinoma (RCC) accounts for 3% of all malignancies, and is the most aggressive cancer of the genitourinary system. Metastatic RCC is naturally resistant to chemotherapy and radiotherapy, and immunotherapy is of little benefit. In recent years, the emergence of molecular-targeted therapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Ding-Wei, Zhang, Hai-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057324/
https://www.ncbi.nlm.nih.gov/pubmed/24944516
http://dx.doi.org/10.2147/OTT.S41828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057324/
https://www.ncbi.nlm.nih.gov/pubmed/24944516
http://dx.doi.org/10.2147/OTT.S41828

Ejemplares similares